Hematuria Cancer Risk Score in combination with Oncuria-Detect for patients undergoing evaluation for hematuria
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The Hematuria Cancer Risk Score (HCRS) and Oncuria-Detect test show strong performance for bladder cancer detection in patients with hematuria. Combining these tests improves accuracy, potentially aiding early diagnosis and cystoscopy selection.
Area Of Science
- Urology
- Oncology
- Diagnostic Medicine
Background
- Bladder cancer diagnosis often follows hematuria evaluation.
- Accurate risk stratification is crucial for timely intervention.
Purpose Of The Study
- To assess the combined performance of the Hematuria Cancer Risk Score (HCRS) and Oncuria-Detect urine biomarker test.
- To evaluate their efficacy in detecting bladder cancer in patients presenting with hematuria.
Main Methods
- A prospective cohort of 365 patients with hematuria were recruited.
- Voided urine samples and clinical data were collected.
- Sensitivity, specificity, and AUC for HCRS and Oncuria were retrospectively analyzed.
Main Results
- HCRS alone showed 90.9% sensitivity and 0.890 AUC; Oncuria-Detect showed 78.2% sensitivity and 0.838 AUC.
- The combination achieved 87.3% sensitivity, 80.6% specificity, and 0.909 AUC.
- Combined approach yielded a 98.7% negative predictive value in microhematuria patients.
Conclusions
- HCRS demonstrates significant predictive power for bladder cancer detection.
- Oncuria-Detect offers incremental improvement when used with HCRS.
- These tests may enhance early detection and patient selection for cystoscopy in primary care settings.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
